Welcome to our dedicated page for BIONTECH SEC filings (Ticker: BNTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BioNTech SE (BNTX) SEC filings page on Stock Titan provides centralized access to the company’s U.S. regulatory disclosures, including current reports on Form 6-K and annual reports on Form 20-F. As a foreign private issuer listed on Nasdaq, BioNTech uses these filings to report financial results, material agreements, strategic transactions and key corporate presentations.
Through its 6-K filings, BioNTech has furnished quarterly financial statements and operating reviews, detailing revenues from its COVID-19 vaccine franchise, collaboration income and research and development spending related to its oncology and mRNA programs. Other 6-Ks incorporate press releases and presentations covering topics such as third quarter results, R&D and AI-focused events, and strategic business updates presented at investor conferences.
Regulatory filings also document major corporate transactions and collaborations. For example, BioNTech has filed 6-Ks that attach press releases on its public exchange offer for all outstanding shares of CureVac N.V. and the subsequent completion of that acquisition, as well as a detailed description of the amended and restated global co-development and co-commercialization agreement with Bristol Myers Squibb for the bispecific antibody pumitamig (BNT327/BMS986545). These documents outline development responsibilities, cost-sharing, profit and loss sharing and intellectual property licensing arrangements.
Investors can use this page to review filings related to clinical and strategic milestones, including R&D day presentations, AI strategy updates and oncology pipeline overviews that are furnished as exhibits to Form 6-K. Stock Titan enhances access to these materials by pairing real-time updates from the SEC’s EDGAR system with AI-powered summaries that explain the key points of lengthy documents such as financial reports, collaboration agreements and transaction-related disclosures.
For those researching BNTX stock, the filings page is a resource for understanding how BioNTech describes its business, reports its financial performance, and records significant agreements and acquisitions in the official SEC record.
BioNTech SE submitted a Form 6-K reporting that it issued a press release on November 26, 2025 about its exchange offer for all outstanding shares of CureVac N.V.. The press release announces the results of CureVac’s extraordinary general meeting and the calculation of the exchange ratio for the offer.
The filing states that this Form 6-K is incorporated by reference into BioNTech’s Form F-4 registration statement. The attached press release, filed as Exhibit 99.1, highlights progress on the exchange offer and notes a December 3, 2025 at 9:00 a.m. Eastern Time expiration for the offer.
BioNTech SE issued a supplement to its prospectus for the public offer to CureVac (CVAC) shareholders, covering an exchange of 15,061,575 newly registered ADSs of BioNTech for all CureVac ordinary shares. The supplement is approved by BaFin, with withdrawal rights exercisable until November 14, 2025.
BioNTech updated financials: nine‑month revenues €1,962.5 million, net loss €831.1 million, and cash and cash equivalents €10,092.9 million. Total cash, cash equivalents and security investments were €16,704.9 million as of September 30, 2025. Q3 results reflect €613.0 million of out‑licensing revenue from the BMS collaboration (part of a
For 2025, management’s forecast assumes revenues €2.6–€2.8 billion, R&D €2.0–€2.2 billion, and SG&A €550–€650 million, and confirms an expected net loss for 2025. The company notes seasonal COVID‑19 vaccine demand, narrower FDA approval scope for its LP.8.1‑adapted vaccine, and ongoing late‑stage oncology development including pumitamig (BNT327).
BioNTech SE issued an Update to its UK Exemption Document for the public offer to CureVac N.V. shareholders, confirming the exchange of 15,061,575 newly registered BioNTech ADSs for all CureVac ordinary shares. The Update incorporates Q3 2025 financials and recent developments.
For the nine months ended September 30, 2025, BioNTech reported revenues of €1,962.5 million, driven by €613.0 million of out‑licensing revenue from its BMS partnership and €1,139.6 million from COVID‑19 vaccine collaborations. Operating loss was €1,082.1 million and net loss €831.1 million, reflecting €678.5 million in expenses related to the GSK/CureVac Settlement Arrangements. Cash, cash equivalents and securities totaled €16,704.9 million as of September 30, 2025.
The company reaffirmed its 2025 outlook: revenues of €2.6–€2.8 billion, research and development expenses of €2.0–€2.2 billion, sales, general and administrative expenses of €550–€650 million, and that it does not expect to report positive net income for 2025. Clinical updates include progress of pumitamig (BNT327) under the BMS collaboration and ongoing oncology programs.
BioNTech SE filed a Form 6‑K noting it hosted an edition of its Innovation Series R&D Day on November 11, 2025, providing an overview of strategy and clinical progress across its pipeline.
The related presentation is attached as Exhibit 99.1. The filing is signed by Chief Financial Officer Ramon Zapata‑Gomez and Chief Operating Officer Dr. Sierk Poetting.
BioNTech SE submitted a Form 6‑K as a foreign private issuer to provide investors with a development update and its latest financial information. On November 3, 2025, the company reported its financial results for the three and nine months ended September 30, 2025, and prepared interim condensed consolidated financial statements for that period. These financial statements, along with an operating and financial review and prospects section, are included as Exhibit 99.1 to the report and are deemed filed under the Securities Exchange Act. The filing is signed on behalf of BioNTech SE by its Chief Financial Officer and Chief Operating Officer.
BioNTech SE furnished a Form 6‑K announcing its third quarter 2025 financial results and corporate update. The company scheduled a conference call for 8:00 am EST on November 3, 2025 to discuss the results. A press release and presentation were provided as Exhibits 99.1 and 99.2 and are incorporated by reference. The materials are designated as furnished and not deemed filed under the Exchange Act unless specifically referenced in a future filing.
BioNTech SE filed Amendment No. 1 to its Schedule TO for the pending exchange offer to acquire all outstanding ordinary shares of CureVac N.V. (CVAC). The offer proposes exchanging BioNTech American Depositary Shares (each representing one ordinary share) for CureVac ordinary shares, on the terms and conditions set out in the Exchange Offer Prospectus and the related Letter of Transmittal.
The amendment updates Item 12 to add exhibits, including a press release and a LinkedIn post, both dated October 22, 2025, incorporated by reference from a Form 6-K and a Rule 425 filing, respectively.
BioNTech SE is pursuing the acquisition of CureVac N.V. via a commenced exchange offer for all outstanding CureVac shares. To facilitate the share-for-ADS exchange, BioNTech has filed a Form F-4 registration statement (including an Exchange Offer Prospectus) and a Schedule TO, while CureVac has filed a Schedule 14D-9. The F-4 has not yet been declared effective by the SEC.
The transaction remains subject to customary conditions, including tender levels and required regulatory approvals, and the parties cite risks such as competing proposals, litigation costs, and potential delays. In Europe, an EU Prospectus has been approved by BaFin for use in Austria, Germany, France, Italy, the Netherlands and Spain, and a UK exemption document has been published. Investors can access the SEC and regional offering documents free of charge through company websites and the SEC’s database.
BioNTech SE commenced a public exchange offer for all outstanding shares of CureVac N.V., advancing its all‑stock acquisition to combine two mRNA pioneers. Each CureVac share will be exchanged for approximately
The offer expires at 9:00 a.m. New York City time on December 3, 2025, unless extended or terminated. Closing conditions include at least 80% of CureVac shares tendered (BioNTech may reduce to 75% under certain circumstances) and required regulatory approvals. Following the offer, the companies plan a corporate reorganization to deliver 100% ownership of CureVac to BioNTech; non‑tendering holders would receive the same consideration, with potential 15% Dutch dividend withholding tax on ADSs issued via the reorganization. CureVac has called an EGM for November 25, 2025, with adoption of specified resolutions a condition to the offer’s expiration.
BioNTech SE announced the commencement of its public exchange offer for all outstanding shares of CureVac N.V., as disclosed in a press release furnished as Exhibit 99.1.
The report states this 6‑K is deemed filed and incorporated by reference into BioNTech’s registration statement on Form F-4 (File No. 333-289468) and its Forms S-8 (File Nos. 333-277105, 333-269740, 333-253263) from the filing date.